199 related articles for article (PubMed ID: 10590673)
1. [A case positive for the inhibitor for coagulation factor V].
Nakagoshi R; Takamiya O; Nakata S; Ishikawa S; Higuchi Y; Okumura N; Ogiso Y
Rinsho Byori; 1999 Oct; 47(10):971-5. PubMed ID: 10590673
[TBL] [Abstract][Full Text] [Related]
2. [Acquired inhibitor against coagulation factor V with severe hematuria].
Hasegawa M; Tanaka T; Kii T; Fujiwara S; Ikeda N; Kinntaka D; Takeuti T; Tanaka H; Ikemoto T
Rinsho Ketsueki; 2003 Sep; 44(9):933-9. PubMed ID: 14577313
[TBL] [Abstract][Full Text] [Related]
3. [A long-lasting idiopathic factor V inhibitor].
Okoshi Y; Akiyama H; Inoue T; Koyama T; Kono N; Matsumura T; Mizuchi D; Mori S; Ohashi K; Sakamaki H
Rinsho Ketsueki; 2003 Jan; 44(1):14-8. PubMed ID: 12649832
[TBL] [Abstract][Full Text] [Related]
4. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
[TBL] [Abstract][Full Text] [Related]
5. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
Lo CY; Jones C; Glader B; Zehnder JL
Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
[TBL] [Abstract][Full Text] [Related]
6. [High-titer idiopathic acquired factor V inhibitor patient showing decreased activities of multiple coagulation factors].
Shimizu I; Ichikawa N; Yotsumoto M; Sumi M; Ueno M; Kobayashi H
Rinsho Ketsueki; 2008 Jun; 49(6):413-6. PubMed ID: 18646609
[TBL] [Abstract][Full Text] [Related]
7. Hyperfibrinogenemia and prolonged clotting times in a Turner syndrome patient with hepatocellular carcinoma.
Zhao X; Wang Z; Cao L; Zhang W; Bai X; Dong N; Yu Z; Ruan C
Blood Coagul Fibrinolysis; 2010 Jul; 21(5):398-405. PubMed ID: 20410814
[TBL] [Abstract][Full Text] [Related]
8. [Clinical cases of acquired coagulation inhibitors].
Yamane T; Hino M; Ota K; Akahori M; Hirai M; Inoue T; Mugitani A; Tatsumi N
Rinsho Byori; 2000 Dec; 48(12):1093-101. PubMed ID: 11215417
[TBL] [Abstract][Full Text] [Related]
9. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors.
de Raucourt E; Barbier C; Sinda P; Dib M; Peltier JY; Ternisien C
Am J Hematol; 2003 Nov; 74(3):187-90. PubMed ID: 14587047
[TBL] [Abstract][Full Text] [Related]
10. Acquired inhibitors of factor V.
Feinstein DI
Thromb Haemost; 1978 Jun; 39(3):663-74. PubMed ID: 705695
[TBL] [Abstract][Full Text] [Related]
11. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
Savage WJ; Kickler TS; Takemoto CM
Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
[TBL] [Abstract][Full Text] [Related]
13. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Caers J; Reekmans A; Jochmans K; Naegels S; Mana F; Urbain D; Reynaert H
Endoscopy; 2003 Jun; 35(6):542-4. PubMed ID: 12783357
[TBL] [Abstract][Full Text] [Related]
14. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency.
Cmolik BL; Spero JA; Magovern GJ; Clark RE
J Thorac Cardiovasc Surg; 1993 Feb; 105(2):222-7; discussion 227-8. PubMed ID: 8429648
[TBL] [Abstract][Full Text] [Related]
15. Acquired factor V inhibitor associated with life-threatening bleeding and a mixing test result that indicated coagulation factor deficiency.
Ashizawa M; Kimura S; Wada H; Sakamoto K; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Kako S; Yamazaki R; Oshima K; Matsuura K; Ohmori T; Madoiwa S; Nishida J; Mimuro J; Tabei K; Sakata Y; Kanda Y
Hematology; 2013 Sep; 18(5):300-4. PubMed ID: 23683688
[TBL] [Abstract][Full Text] [Related]
16. [A patient with hemorrhage originating from an unknown coagulation pathway inhibitor].
Komiyama Y; Munakata M; Masuda M; Kagawa H; Fukuhara S; Takahashi H
Rinsho Byori; 2000 Dec; 48(12):1086-92. PubMed ID: 11215416
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
18. [Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis].
Takaku T; Kuriyama Y; Shoji N; Otawa M; Gotoh A; Miyazawa K; Fukutake K; Ohyashiki K
Rinsho Ketsueki; 2002 Dec; 43(12):1050-4. PubMed ID: 12607994
[TBL] [Abstract][Full Text] [Related]
19. [Factor V inhibitor with double cancer].
Okajima A; Horii J; Nasu K; Niki Y; Akasaka K; Yamashita H; Sugimoto M; Yoshioka A
Rinsho Ketsueki; 1989 Apr; 30(4):514-9. PubMed ID: 2769972
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases.
Wiwanitkit V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):485-8. PubMed ID: 17000894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
